Ublituximab
Approved · EMAAlso known as Briumvi.
Recent clinical, regulatory, research and industry developments relating to this drug.
Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)
Evaluating Safety and Efficacy of Ublituximab in Participants With Schizophrenia
An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis
Evaluating Safety, Efficacy and Pharmacokinetics of a Modified Regimen of Ublituximab (ENHANCE )
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
Evidence ↗Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)
An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis
Recent completions
Trials that read out recently, adding to the completed evidence base.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.